Quark Pharmaceuticals, Inc.

The UK’s Silence Therapeutics PLC and Alnylam Pharmaceuticals Inc. have agreed to settle litigation in which the former accused the latter of infringing its European patents. Alnylam has agreed to

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

As Alnylam Pharmaceuticals Inc. finalizes plans to file the first RNA interference therapeutic, patisiran, the UK's Silence Therapeutics PLC has begun the next phase of its legal moves to clai